TPST

Market-moving news on Tempest Therapeutics (NASDAQ: TPST): filings, earnings, deals and other events, from REDFILED.

Tempest Therapeutics has taken an option on technology from a Chinese biotech partner.

TPST

TEMPEST THERAPEUTICS (TPST) Signs Option and License Deal With China's Senlang

Tempest disclosed an exclusive collaboration, option and license agreement with Hebei Senlang Biotechnology covering rights to develop and commercialize licensed products.

Tempest Therapeutics is developing in vivo CAR-T therapies for cancer and autoimmune disease.

TPST

TEMPEST THERAPEUTICS Raises $2.5M Upfront in Private Placement

The clinical-stage biotech is selling 3.1 million shares at $0.805 with two warrant tranches that could add about $5 million more.